Journal: Journal for Immunotherapy of Cancer
Article Title: Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapy
doi: 10.1136/jitc-2023-007354
Figure Lengend Snippet: Association of immune marker signatures with PSA response and OS. (A) The correlations between the 24 non-redundant (ie, those without high Spearman correlations among each other) set of evaluated tumor immune microenvironment gene expression signatures (ρ is shown), (B) OS of the group with tumor immune gene expression signature analysis is not significantly different from the overall cohort of Lu-PSMA therapy treated patients at our institution and (C) the cDNA yield from RNA extracted from tumor samples, best PSA response and relative expression signature level (z-scores, higher values indicate higher signature) of immune-related gene signatures are shown correspondingly to identify patterns of signatures with regard to PSA response. Patients with higher PD-L2 signature (above the median) have longer OS time (D) and greater PSA responses (E). Lu-PSMA, [ 177 Lu]Lutetium-PSMA-617; mo., months; OS, overall survival; PD-L1, programmed death-ligand 1; PSA, prostate-specific antigen.
Article Snippet: RNA was extracted from formalin-fixed paraffin embedded tumor tissue and underwent cDNA amplification, oligonucleotide microarray hybridization and microarray quality control in a Clinical Laboratory Improvement Amendments-certified laboratory (Veracyte, San Diego, California, USA) as previously described.
Techniques: Marker, Gene Expression, Expressing